Genital candidiasis epidemiology and demographics: Difference between revisions
(→Age) |
m (Changes made per Mahshid's request) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 17: | Line 17: | ||
===HIV Infection=== | ===HIV Infection=== | ||
Oro-pharyngeal candidiasis used to be a common opportunistic infection in HIV-infected persons (prior to the introduction of highly active antiretroviral therapy [HAART]). | Oro-pharyngeal candidiasis used to be a common opportunistic infection in HIV-infected persons (prior to the introduction of highly active antiretroviral therapy ([[HAART]]). | ||
==References== | ==References== | ||
| Line 23: | Line 23: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 17:48, 18 September 2017
Template:Genital candidiasis Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
It is the fourth most common cause of nosocomial bloodstream infections. Incidence is 8 cases per 100,000 in the general population. Mortality rate is almost 50% with bloodstream and disseminated infection.
Epidemiology and Demographics
Gender
Nearly 75% of all adult women have had at least one genital "yeast infection" in their lifetime. On rare occasions, men may also experience genital candidiasis. VVC occurs more frequently and more severely in people with weakened immune systems.
Age
Incidence is higher among neonates.
Race
Incidence is higher among African-Americans.
HIV Infection
Oro-pharyngeal candidiasis used to be a common opportunistic infection in HIV-infected persons (prior to the introduction of highly active antiretroviral therapy (HAART).
References